series-c-plus
Stage
1
Investors
About
ORIC Pharmaceuticals is a clinical-stage oncology company developing small molecule therapies aimed at overcoming cancer treatment resistance mechanisms, with multiple drug candidates in Phase 1 and Phase 3 trials targeting resistance pathways in solid tumors.
Explore ORIC Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.